@article{Shen2026, 
author = {Yiyang Shen and Xiaofei Jiao and Yuanjia Wen and Zikun Peng and Xuejiao Zhao and Jiahao Liu and Qinglei Gao},
title = {Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials},
year = {2026},
journal = {Cancer Innovation},
volume = {5},
number = {3},
pages = {e70065},
keywords = {antibody‐drug conjugates, clinical trials, gynecologic cancers, immunotherapy, treatment advances},
url = {https://www.sciopen.com/article/10.1002/cai2.70065},
doi = {10.1002/cai2.70065},
abstract = {Gynecologic cancers remain a major global health burden for women. Their management has evolved toward a gynecologic oncologist‐led multimodal paradigm. While these approaches have improved outcomes, critical limitations persist, including challenges in decision‐making during surgical procedures and suboptimal efficacy coupled with frequent resistance and substantial toxicities during medical management. Recent high‐quality clinical trials have helped refine these areas. In early‐stage cervical cancer, sentinel lymph node biopsy has emerged as a safe and effective alternative to systematic lymphadenectomy, preserving oncologic outcomes while minimizing morbidity. In advanced ovarian cancer, primary debulking surgery has been established as superior to neoadjuvant chemotherapy followed by interval debulking surgery in fit patients treated at experienced centers. Meanwhile, immunotherapy demonstrates promise through strategic combinations, including dual checkpoint inhibition and triplet regimens incorporating chemotherapy and anti‐angiogenic agents. Antibody‐drug conjugates (ADCs) directed against folate receptor alpha (FRα) and tissue factor (TF) have shown durable responses in biomarker‐selected populations. By critically synthesizing these advances, this review seeks to delineate the clinical utility of emerging therapies, highlight knowledge gaps, and inform evidence‐based decision‐making for clinicians and researchers.}
}